Adiponectin level and left ventricular hypertrophy in Japanese men

Hypertension

Volumn 49, Issue 6, 2007, Pages 1448-1454

  Mitsuhashi, Hirotsugu ^a   Yatsuya, Hiroshi ^a   Tamakoshi, Koji ^a   Matsushita, Kunihiro ^a   Otsuka, Rei ^a   Wada, Keiko ^a   Sugiura, Kaichiro ^a   Takefuji, Seiko ^a   Hotta, Yo ^a   Kondo, Takahisa ^a   Murohara, Toyoaki ^a   Toyoshima, Hideaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adiponectin; Electrocardiography; Epidemiologic study; Japanese; Left ventricular hypertrophy

Indexed keywords

ADIPONECTIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONFIDENCE INTERVAL; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE;

ADIPONECTIN; ADULT; AGED; BODY MASS INDEX; ELECTROCARDIOGRAPHY; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; JAPAN; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PREVALENCE;

EID: 34249287973     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.106.079509     Document Type: Article

References (47)

1. Iacobellis G, Pistilli D, Gucciardo M, Leonetti F, Miraldi F, Brancaccio G, Gallo P, di Gioia CR. Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease. Cytokine. 2005;29:251-255.
2. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24:29-33.
3. Matsushita K, Yatsuya H, Tamakoshi K, Wada K, Otsuka R, Takefuji S, Sugiura K, Kondo T, Murohara T, Toyoshima H. Comparison of circulating adiponectin and proinflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler Thromb Vasc Biol. 2006;26:871-876.
4. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, Fu Y, Motone M, Yamamoto K, Matsuo A, Ohashi K, Kihara S, Funahashi T, Rakugi H, Matsuzawa Y, Ogihara T. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. 2004;43:1318-1323.
5. Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR, Kumada M, Sato K, Schiekofer S, Ohashi K, Funahashi T, Colucci WS, Walsh K. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med. 2004;10:1384-1389.
6. Walsh RA. Molecular and cellular biology of the normal, hypertrophied, and failing heart. In: Fuster V, Alexander RW, O'Rourke RA, Roberts R, King III SB, Wellens HJ. Hurst's The Heart, 10th ed. New York, NY: McGraw-Hill; 2001:115-125.
7. Ilercil A, Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Welty TK, Robbins DC, Fabsitz RR, Howard BV, Lee ET. Relationship of impaired glucose tolerance to left ventricular structure and function: the Strong Heart Study. Am Heart J. 2001;141:992-998.
8. Thrainsdottir IS, Hardarson T, Thorgeirsson G, Sigvaldason H, Sigfusson N. Survival and trends of occurrence of left ventricular hypertrophy, gender differences, 1967-92: the Reykjavik Study. J Intern Med. 2003;253:418-424.
9. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically-determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
10. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312-318.
11. Kannel WB. Left ventricular hypertrophy as a risk factor: the Framingham experience. J Hypertens. 1991;9(suppl):S3-S8.
12. Bots ML, Nikitin Y, Salonen JT, Elwood PC, Malyutina S, Freire de Concalves A, Sivenius J, Di Carlo A, Lagiou P, Tuomilehto J, Koudstaal PJ, Grobbee DE. Left ventricular hypertrophy and risk of fatal and non-fatal stroke. EUROSTROKE: a collaborative study among research centres in Europe. J Epidemiol Community Health. 2002;56(suppl 1):i8-i13.
13. Okin PM, Devereux RB, Nieminen MS, Jern S, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Julius S, Snapinn S, Dahlof B; LIFE Study Investigators. Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients. Hypertension. 2004;44:48-54.
14. Nakamura K, Okamura T, Hayakawa T, Kadowaki T, Kita Y, Okayama A, Ueshima H; NIPPON DATA90 Research Group. Electrocardiogram screening for left high R-wave predicts cardiovascular death in a Japanese community-based population: NIPPON DATA90. Hypertens Res. 2006;29:353-360.
15. Ministry of Health, Labour and Welfare. The Fifth National Survey of Cardiovascular Diseases. Tokyo, Japan: Ministry of Health, Labour and Welfare; 2002:291.
16. Hong SJ, Park CG, Seo HS, Oh DJ, Ro YM. Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Blood Press. 2004;13:236-242.
17. Dahlof B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. The Losartan Intervention For Endpoint Reduction (LIFE) in Hypertension Study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens. 1997;10:705-713.
18. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlof B; LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292:2343-2349.
19. Celik T, Iyisoy A, Kursaklioglu H, Kardesoglu E, Kilic S, Turhan H, Yilmaz MI, Ozcan O, Yaman H, Isik E, Fici F. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens. 2006;24:591-596.
20. Okin PM, Jern S, Devereux RB, Kjeldsen SE, Dahlof B; LIFE Study Group. Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention for Endpoint (LIFE) Reduction in hypertension study. Hypertension. 2000;35:13-18.
21. Dahlof B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension. 1998;32:989-997.
22. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. 1949. Ann Noninvasive Electrocardiol. 2001;6:343-368.
23. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltageduration products. J Am Coll Cardiol. 1995;25:417-423.
24. McGavock JM, Victor RG, Unger RH, Szczepaniak LS; American College of Physicians and the American Physiological Society. Adiposity of the heart, revisited. Ann Intern Med. 2006;144:517-524.
25. Ciardullo AV, Azzolini L, Bevini M, Cadioli T, Daghio MM, Guidetti P, Lorenzetti M, Malavasi P, Morellini A, Carapezzi C. A diagnosis of left ventricular hypertrophy on ECG is associated with a high cardiovascular risk: findings from a 40- to 69-year-old cohort in general practice. Fam Pract. 2004;21:63-65.
26. Huang Y, Walker KE, Hanley F, Narula J, Houser SR, Tulenko TN. Cardiac systolic and diastolic dysfunction after a cholesterol-rich diet. Circulation. 2004;109:97-102.
27. Liao Y, Takashima S, Maeda N, Ouchi N, Komamura K, Shimomura I, Hori M, Matsuzawa Y, Funahashi T, Kitakaze M. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res. 2005;67:705-713.
28. Rutter MK, Parise H, Benjamin EJ, Levy D, Larson MG, Meigs JB, Nesto RW, Wilson PW, Vasan RS. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation. 2003;107:448-454.
29. Murakami H, Ura N, Furuhashi M, Higashiura K, Miura T, Shimamoto K. Role of adiponectin in insulin-resistant hypertension and atherosclerosis. Hypertens Res. 2003;26:705-710.
30. Sega R, Trocino G, Lanzarotti A, Carugo S, Cesana G, Schiavina R, Valagussa F, Bombelli M, Giannattasio C, Zanchetti A, Mancia G. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). Circulation. 2001;104:1385-1392.
31. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T. Adiponectin as a biomarker of the metabolic syndrome. Circ J. 2004;68:975-981.
32. Chan AY, Soltys CL, Young ME, Proud CG, Dyck JR. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem. 2004;279:32771-32779.
33. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of left ventricular hypertrophy: test performance in relation to definition of hypertrophy and presence of obesity. J Am Coll Cardiol. 1996;27:124-131.
34. Levy D, Labib SB, Anderson KM, Christiansen JC, Kannel WB, Castelli WP. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation. 1990;81:815-820.
35. Abergel E, Tase M, Menard J, Chatellier G. Influence of obesity on the diagnostic value of electrocardiographic criteria for detecting left ventricular hypertrophy. Am J Cardiol. 1996;77:739-744.
36. Alpert MA, Terry BE, Cohen MV, Fan TM, Painter JA, Massey CV. The electrocardiogram in morbid obesity. Am J Cardiol. 2000;85:908-910, A10.
37. Okin PM, Roman MJ, Devereux RB, Kligfield P. ECG identification of left ventricular hypertrophy. Relationship of test performance to body habitus. J Electrocardiol. 1996;29 Suppl:256-261.
38. Danias PG, Tritos NA, Stuber M, Kissinger KV, Salton CJ, Manning WJ. Cardiac structure and function in the obese: a cardiovascular magnetic resonance imaging study. J Cardiovasc Magn Reson. 2003;5:431-438.
39. Rao PS, Monarrez CN. Electrocardiographic differentiation of posterobasal left ventricular hypertrophy from right ventricular hypertrophy. J Electrocardiol. 1981;14:25-30.
40. The Examination Committee of Criteria for 'Obesity Disease' in Japan, Japan Society for the Study of Obesity. New criteria for 'Obesity Disease' in Japan. Circ J. 2002;66:987-992.
41. Tsugane S, Sasaki S, Tsubono Y. Under- and overweight impact on mortality among middle-aged Japanese men and women: a 10-y follow-up of JPHC study cohort I. Int J Obes Relat Metab Disord. 2002;26:529-537.
42. Shiwaku K, Anuurad E, Enkhmaa B, Nogi A, Kitajima K, Shimono K, Yamane Y, Oyunsuren T. Overweight Japanese with body mass indexes of 23.0 -24.9 have higher risks for obesity-associated disorders: a comparison of Japanese and Mongolians. Int J Obes Relat Metab Disord. 2004;28:152-158.
43. Vaccaro O, Cardoni O, Cuomo V, Panarelli W, Laurenzi M, Mancini M, Riccardi G, Zanchetti A; Gubbio Study Research Group. Relationship between plasma insulin and left ventricular mass in normotensive participants of the Gubbio Study. Clin Endocrinol (Oxf). 2003;58:316-322.
44. Smith J, Al-Amri M, Sniderman A, Cianflone K. Leptin and adiponectin in relation to body fat percentage, waist to hip ratio and the apoB/apoA1 ratio in Asian Indian and Caucasian men and women. Nutr Metab. 2006;3:18.
45. Smilde TD, Asselbergs FW, Hillege HL, Voors AA, Kors JA, Gansevoort RT, van Gilst WH, de Jong PE, Van Veldhuisen DJ. Mild renal dysfunction is associated with electrocardiographic left ventricular hypertrophy. Am J Hypertens. 2005;18:342-347.
46. Isobe T, Saitoh S, Takagi S, Takeuchi H, Chiba Y, Katoh N, Shimamoto K. Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study. Eur J Endocrinol. 2005;153:91-98.
47. Liu JE, Roman MJ, Pini R, Schwartz JE, Pickering TG, Devereux RB. Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure. Ann Intern Med. 1999;131:564-572.